King Faisal Specialist Hospital and Research Centre Utilizes Early Cancer Detection Technology for 50 Genes

King Faisal Specialist Hospital and Research Centre (KFSH&RC) has achieved a significant milestone by successfully conducting liquid biopsies on patients spanning various age groups. This innovative approach offers a safer alternative to conventional tissue biopsies. Notably, KFSH&RC stands out as the first healthcare facility in the Middle East to adopt this cutting-edge technology.

This groundbreaking method is distinguished by its ability to detect approximately 50 genes associated with cancer and over 3,000 genetic mutations. This represents a pivotal advancement in patient care, eliminating the need to extract tissue from the affected area for examination. This transformative step greatly enhances healthcare outcomes and elevates the overall patient experience.

Liquid biopsy offers advantages over traditional tissue biopsies. It’s less invasive, involving a simple 10 ml blood sample that can be repeated during treatment. Additionally, it provides high accuracy in swiftly detecting tumor biomarkers, predicting treatment responses, identifying emerging mutations, and confirming the absence of tumor recurrence, marking a significant advancement in cancer science.

This technology presents a safer alternative to traditional biopsies for patients facing challenges in accessing affected tissue without surgical intervention, as seen in cases like lung cancer. It is particularly beneficial for elderly patients, for whom a lung tissue biopsy may not be suitable due to the potential for severe complications associated with it.

As a strategic health partner at the Global Health Exhibition in Riyadh from October 29 to 31, KFSH&RC will showcase its pavilion in the accompanying exhibition, where visitors can explore Liquid biopsy technology and various other healthcare solutions and technologies.

Liquid biopsy technology holds promise for other stages of cancer treatment at KFSH&RC. Through the routine use of the test, it is possible to build a database of tumor-causing mutations in the local community, which helps in early diagnosis of cancer before tumors form, in addition to tracking changes in the patient’s condition, frequently during treatment, allowing timely adjustments to treatment plans and preventing worsening of the condition.

This achievement is a part of KFSH&RC’s ongoing commitment to harness advanced technologies for enhancing operational excellence and patient care. The test facilitates swift clinical decision-making for cancer patient management and reduces both the testing time and its process through full automation.

KFSH&RC stands as one of the world’s prominent institutions in delivering specialized healthcare, leading the way in innovation, and serving as an advanced hub for medical research and education. Furthermore, it actively endeavors to advance medical technologies and elevate global healthcare standards through collaborations with significant local, regional, and international organizations, aiming to deliver world-class clinical, research, and educational services.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

QScout ™ is the first hematology platform designed for simple, fast operation at the point-of-care. It provides lab-grade, patient-side results that caregivers use to screen for health conditions including infection, leukemia, and other blood-related cancers, allergies, and many more.
The BD MiniDraw™ Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger by a trained healthcare worker, without the need for a phlebotomist to collect blood from a vein.
"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.

By using this website you agree to accept Medical Device News Magazine Privacy Policy